Adaptive Phage Therapeutics (APT) is a clinical stage company focused on developing precision phage therapy to address the growing threat of multi-drug resistant (MDR) bacterial infections. Founded on pioneering research by NIH scientist Dr. Carl R. Merril and further explored by the US Navy's Biological Defense Research Directorate, APT aims to provide effective therapeutic responses where traditional antibiotics fail. The company operates in the biotechnology and healthcare market, primarily serving hospitals, healthcare providers, and patients affected by MDR infections. APT's business model revolves around the development and commercialization of phage-based treatments, including a phage susceptibility test in collaboration with the Mayo Clinic. Revenue is generated through clinical trials, partnerships, and eventual commercialization of their therapies.

Keywords: precision phage therapy, multi-drug resistant bacteria, clinical stage, biotechnology, healthcare, therapeutic response, phage susceptibility test, collaboration, commercialization, MDR infections.